Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | HRH1 | P35367 | 3/20 | 0.85 |
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | HTR2A | P28223 | 2/20 | 0.85 |
| ▸ | HTR2B | P41595 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | DRD2 | P14416 | 2/20 | 0.85 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.85 |
| ▸ | NPC1 | O15118 | 1/20 | 0.85 |
| ▸ | MLNR | O43193 | 1/20 | 0.85 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 1/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carebastine SCHEMBL26674069 | 0.95 | LMNA (0.78) | LMNAHRH1DRD3HTR2AHTR2B | |
| SCHEMBL12021981 | 0.92 | DRD3 (0.73) | LMNAHRH1DRD3HTR2AHTR2B | |
| Ebastine SCHEMBL18467 | 0.92 | ADRA1D (1.00) | LMNAHRH1DRD3HTR2AHTR2B | |
| Carebastine SCHEMBL26674051 | 0.92 | ADRA1D (0.81) | LMNAHRH1DRD3HTR2AHTR2B | |
| SCHEMBL6101514 | 0.92 | ADRA1D (0.81) | LMNAHRH1DRD3HTR2AHTR2B | |
| Carebastine SCHEMBL26674058 | 0.92 | ADRA1D (0.81) | LMNAHRH1DRD3HTR2AHTR2B | |
| Ebastine SCHEMBL25205252 | 0.91 | ADRA1D (0.98) | LMNAHRH1DRD3HTR2AHTR2B | |
| Carebastine SCHEMBL26674085 | 0.91 | HTR2A (0.71) | LMNAHRH1DRD3HTR2AHTR2B | |
| Ebastine SCHEMBL2546560 | 0.90 | ADRA1D (0.96) | LMNAHRH1DRD3HTR2AHTR2B | |
| SCHEMBL28837707 | 0.90 | ADRA1D (0.78) | LMNAHRH1DRD3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | CHENGDU SHIBEIKANG BIOMEDICAL TECH CO LTD (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4570823-A1 | IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-BETA OLIGOMERS | Shen Zhen Wisdom Biopharm Co., Ltd. (CN) | 2025-06-18 | — | — | EP | claimed |
| EP-4520752-A1 | CAREBASTINE SALT AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2025-03-12 | — | — | EP | claimed |
| WO-2024032822-A9 | IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-β OLIGOMERS | 深圳智源生物医药有限公司 | 2024-09-06 | — | — | WO | claimed |
| WO-2024146022-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF CAREBASTINE P-TOLUENESULFONATE | 成都施贝康生物医药科技有限公司 | 2024-07-11 | — | — | WO | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| WO-2024032822-A1 | IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-β OLIGOMERS | 深圳智源生物医药有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2002032893-A2 | PIPERIDINE COMPOUNDS AS ANTI-ALLERGIC | SCHERING CORPORATION (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1117405-A2 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2001-07-25 | — | — | EP | claimed |
| US-6103735-A | IN COMBINATION, ANTAGONISTS OF A NEUORKININ, A HISTAMINE 3 AND A HISTAMINE 1; ANTIALLERGENS; RHINITIS, ASTHMA AND RELATED DISORDERS; COUGH, WHEEZING; SNEEZING, ITCHING, RUNNY NOSE, NASAL CONGESTION, REDNESS OF THE EYE, TEARING | SCHERING CORPORATION (US) | 2000-08-15 | — | — | US | claimed |
| US-6100279-A | HISTAMINE-H3 RECEPTOR ANTAGONIST; ANTIALLERGENIC AGENTS, ANTIASTHMATICS | SCHERING CORPORATION (US) | 2000-08-08 | — | — | US | claimed |
| WO-2000021512-A2 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| US-5990147-A | 1-((3,5-DICHLOROPHENYL)UREYLENEMETHYL),4-(IMIDAZOL-5-YLMETHYL-BENZENE; ANTIALLERGENS; ANTIINFLAMMATION AND HYPERTENSIVE AGEMTS; GLAUCOMA, SLEEPING DISORDERS, HYPER- AND HYPOMOTILITYOF THE GASTRO-INTESTINAL TRACT; CENTRAL NERVOUS | SCHERING CORPORATION (US) | 1999-11-23 | — | — | US | claimed |
| EP-0920315-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-09 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| US-5204249-A | PROCESS FOR THE PREPARATION OF CAREBASTINE AND SIMILAR MATERIALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | LMNA 1999/4885HRH1 7/4885DRD3 4013/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | LMNA 1999/4885HRH1 7/4885DRD3 4013/4885 |
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | HRH4, SLC7A1, HRH1 | LMNA 4624/4885HRH1 3/4885DRD3 2883/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | LMNA 1999/4885HRH1 7/4885DRD3 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.